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a  b  s  t  r  a  c  t
Myelodysplastic  syndromes  (MDS)  are  oligoclonal  hematopoietic  disorders  characterized  by  peripheral
cytopenias  with  anemias  being  the most  prevalent  feature.  The  majority  of patients  will depend  on
regular  transfusions  of  packed  red blood  cells  (PRBC)  during  the  course  of the disease.  Particularly  patients
with MDS  and low  risk  for transformation  into  acute  myeloid  leukemia  and  low  risk  of early  death  will
receive  PRBC  transfusions  on a regular  basis,  which  puts  them  at  high  risk  for  transfusional  iron  overload.
Transfusion  dependence  has  been  associated  with  negative  impact  on organ  function  and  reduced  life
expectancy.
Recently, several  retrospective  but  also  some  prospective  studies  have  indicated,  that  transfusion
dependent  patients  with  MDS  might  benefit  from  consequent  iron  chelation  with  regard  to  morbidity  and
mortality.  However,  low  treatment  adherence  due  to  adverse  events  mainly  gastrointestinal  in  nature  is
an  important  obstacle  in achieving  sufficient  iron  chelation  in MDS patients.  Here,  we  will  summarize  and
discuss  the existing  data  on  Deferasirox  in  low  risk  MDS  published  so  far  and  provide  recommendations
for  optimal  management  of  gastrointestinal  adverse  events  during  iron  chelation  aiming  at improving
treatment  compliance  and, hence,  sufficiently  removing  excess  iron  from  the  patients.
©  2015  Published  by Elsevier  Ltd.
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1. Introduction
Myelodysplastic syndromes (MDS) are bone marrow failures
that show an increasing incidence in the elderly [1]. They are
recognized as oligoclonal hematopoietic disorders characterized
by peripheral cytopenias with anemias being the most prevalent
cytopenic feature. The majority of patients is either transfusion
dependent for red blood cells or becomes transfusion dependent
during the course of the disease. Particularly patients with MDS
and low risk for transformation into acute myeloid leukemia and
low risk of early death will receive packed red blood cell (PRBC)
transfusions on a regular basis, which puts them at high risk for
transfusional iron overload (IOL) since the human organism has no
natural means of removing excess iron. Transfusion dependence
has been associated with negative impact on organ function and
reduced life expectancy [2,3], though data are conflicting [4].
IOL leads to deposition of iron in organs such as the liver, the
heart and the endocrine glands. In patients with inherited anemias
such as patients suffering from thalassemia or sickle cell disease,
repetitive transfusions and consecutive IOL can cause organ dam-
age leading to liver cirrhosis, cardiac failure or diabetes mellitus
[5–7].
In addition to transfusion associated IOL, some patients with
MDS  exhibit high ferritin levels although they have never received
any transfusions, indicating a disturbed iron metabolism. Advances
in the understanding of iron physiology and pathophysiology sug-
gest, that insufficient erythropoiesis in MDS  patients leads to
decreased hepcidin levels and consecutively increased intestinal
iron absorption. In fact, the recently discovered erythroid regulator
erythroferrone links aberrant erythropoiesis to hepcidin suppres-
sion with consecutive increased dietary iron absorption [8]. Of note,
erythroid progenitors in MDS  patients show a particularly high
expression of erythroferrone, which provides a plausible explana-
tion, that IOL can be evident in MDS  patients, who  never received
any transfusions of PRBC [9].
The introduction of efficacious iron chelation with deferiox-
amine (DFO) improved the outcome of patients with transfusion
dependent anemias such as thalassemia and sickle cell disease dra-
matically [5,6]. This might be mainly due to the elimination of the
so-called labile plasma iron (LPI), which catalyzes the generation
of reactive oxygen species (ROS). ROS exert a high reactivity with
cellular organelles and structures such as the plasma membrane,
mitochondria, intracellular enzymes and nucleic acids inducing cel-
lular dysfunction and cell death [10].
Although DFO has demonstrated high efficacy in treatment of
IOL continuous and subcutaneous administration is necessary to
provide sufficient coverage of LPI due to the short plasma half-life
of DFO. It has been shown that this way of application is a major
obstacle for providing a sufficient iron chelation (IC). Patients are
affected by the inconvenient administration, which subsequently
leads to lower adherence to the treatment and insufficient IC result-
ing in increased morbidity and mortality [5,6]. Interestingly, IC has
been shown to improve hematopoiesis in some patients [11–13].
Although the exact mechanism is not clear yet improvement of
hematopoiesis might be due to a reduction of oxidative stress in
hematopoietic progenitors in general and erythropoietic progeni-
tors in particular [10].
Deferasirox (DFX) is an orally administered iron chelator, which
has demonstrated high efficacy in reduction of iron burden in
patients with transfusional IOL. The plasma half-life of DFX is
approximately 13 h, which allows a once daily administration
providing 24 h coverage of LPI [14]. It showed a similar efficacy
in lowering iron burden as compared to DFO in MDS  patients
[15,16].
Recently, several retrospective but also some prospective stud-
ies have indicated, that transfusion dependent patients with MDS
might benefit from consequent iron chelation with regard to mor-
bidity and mortality [17–24]. However, gastrointestinal adverse
events leading to reduced quality of life in these patients are asso-
ciated with low treatment adherence and are considered as a
major obstacle in achieving consequent and effective iron chela-
tion with DFX. Here, we  will update our recommendations on the
management of gastrointestinal disturbances during treatment of
iron-overloaded patients with MDS  using DFX [25].
2. Potential benefits of iron chelation in transfusion
dependent patients with MDS
It is well established that IOL has a deleterious effect in patients
with inherited anemia, i.e. thalassemia and sickle cell disease. Intro-
duction of iron chelation significantly improved survival in those
patients by preventing particularly cardiac failure, but also hepatic
and pancreatic damage and pituitary insufficiency [5,6]. The effect
of IOL in MDS  patients, however, is controversial. The pros and cons
for and against iron chelation range from consideration of excess
iron as a toxin that needs to be removed on the one hand and
regarding the iron issue as a paranoia on the other hand [26–28].
Advocates for initiation of iron chelation refer to the usually older
age of MDS  patients presenting with clinical significant comorbidi-
ties, which render them more prone to iron-related organ toxicity.
In contrast, the opponents consider the effect of IOL clinically less
relevant due to the reduced life expectancy in anemic patients with
MDS  as compared to patients with other anemias.
There is evidence, that transfusion dependency and develop-
ment of IOL might have a negative impact on patient survival [2,29].
Consequently, several retrospective and observational studies have
suggested a beneficial influence of iron chelation on mortality and
morbidity in MDS  patients with transfusional IO [17–24].
DFX has shown its efficacy in sufficiently reducing serum fer-
ritin in transfusion dependent patients with MDS  and IOL  [30–34].
Although mainly obtained from retrospective trials, data indicate
that DFX might improve survival and reduce morbidity in such
patients. Moreover, improvement of hematopoiesis during DFX
treatment was reported by several groups with erythroid, neu-
trophil and platelet responses seen in 6–21%, 3–17%, and 15–30%
of the patients, respectively, including transfusion independency
for PRBC at 12 months of DFX treatment of 12% in a trial from the
Italian GIMEMA group [33–35].
However, since it is likely that physicians estimate a patient’s
prognosis not only on the basis of disease-related risk scores but
also according to the patient‘s general fitness, there might be a
systematic bias in all of the aforementioned studies, because it can-
not be excluded that in patients with a better performance status
iron chelation may  have been more likely to be initiated. This cir-
cumstance has recently been emphasized in a Cochrane analysis,
which also underlined the need for well controlled randomized
trials [36].
3. Gastrointestinal disturbances during Deferasirox
treatment
Although DFX is highly effective in removing excess iron from
iron overloaded MDS  patients, high dropout rates of approximately
50% of patients within one year were observed in the majority of
clinical studies [30,32–34]. The main reasons for discontinuation
were adverse events, gastrointestinal in nature in the majority of
patients as discussed below.
Gattermann et al. reported, that of 327 MDS  patients 66% expe-
rienced adverse events, that were considered to be drug related.
Gastrointestinal events were the most frequent AEs with diar-
rhea, nausea, vomiting and abdominal pain occurring in 33%,
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13%, 8%, and 8%, of the patients, respectively. Of 341 enrolled
patients, 25 patients discontinued the DFX treatment due to gas-
trointestinal AEs [30]. In the one year GIMEMA trial, 43% of the
patients completed the trial. The main reason for discontinuation
were adverse events in 33% of the patients and of the treatment
related adverse events 45% were gastrointestinal in nature [34].
Although adverse events were mild to moderate in the majority of
cases, they limited the adherence of the patients to a consequent
and sufficient treatment schedule.
Interestingly, subgroup analyses of the EPIC cohort revealed that
GI disturbances were more frequent in the MDS  patient cohort as
compared to patients with inherited anemias such as thalassemia,
which might be an indication of a higher susceptibility of the elderly
patients to DFX with regard to GI disturbances.
Taken together, to provide a sufficient coverage of iron over-
loaded MDS  patients with DFX, effective prevention and treatment
of gastrointestinal adverse events is crucial.
4. Management of gastrointestinal adverse events
On July 18th 2014 an expert panel had an extensive discussion
regarding optimal dosing schedules and procedures to manage gas-
trointestinal disturbances that frequently impair the success of iron
chelation in iron overloaded MDS  patients using DFX. The panel
agreed that gastrointestinal disturbances interfere with the daily
routines of the patients and affect their quality of life and should
therefore be prevented as far as possible. If adverse events cannot
be prevented they should be treated effectively. Prior to treatment
initiation patients should be informed in detail about the neces-
sity of the treatment and the possible adverse events, particularly
gastrointestinal disturbances.
Although no data from clinical trials do exist, that initiating
the treatment at low DFX doses and increasing the dose according
to tolerability and efficacy might prevent gastrointestinal distur-
bances, the panel agreed that this might be a helpful strategy
to start chelation with DFX. The drug should be initiated at a
flat dose of 500 mg  once daily. If tolerability is good, the dose
should be increased weekly by 500 mg  per day to the target dose,
which should be calculated on the basis of the serum ferritin
level and transfusion frequency. For patients with a serum ferritin
>1000 ng/L, who receive more than 2 units PRBC per 4 weeks but
less than 2 units per 2 weeks, the target dose should be 30 mg/kg
body weight per day. For patients with a higher transfusion fre-
quency and high serum ferritin levels who do not respond to a
dose of 30 mg/kg body weight, even target doses of 40 mg/kg body
weight might be necessary to reduce body iron. For iron overloaded
patients with transfusion frequencies of less than 2 units PRBC, DFX
Table 1
Recommendations for prevention of gastrointestinal disturbances.
Time of administration
– Pre-prandial evening DFX dosing (based on expert experience)
–  DFX dosing (at least 30 min) before dinner
– Do not recommend to take with food
Starting dose and escalation
– Initiation of DFX dosing with low dose, e.g. 500 mg
– Dose escalation to target dose has to be done in timely fashion
–  Target dose should be calculated based on serum ferritin and transfusion
frequency
–  B.i.d. dosing not recommended. Considering the negative impact on
patient adherence and the lack of PK and clinical data experts advise against
divided dosing
Use of prophylactics
– Do not use prophylactic anti-acidic drugs (PPI); treat only symptomatically
if  needed
– Patients with lactose intolerance are not frequent. There is not enough
evidence to recommend excluding for lactose intolerance before treatment
with deferasirox, or to recommend the prophylactic use of Lactobacillus
preparations
–  Potential effect of new formulations on gastrointestinal disturbances has
to  be evaluated
doses of 20 mg/kg body weight might be enough to reduce body
iron (see Fig. 1). Of note, patients should be closely followed-up
with regular determination of body iron status, to avoid under-
treatment (but also over-treatment) by failing to achieve sufficient
and adequate drug doses to eliminate iron from the body either
as “induction” therapy or maintenance. For a summary of recom-
mendations for the prevention of gastrointestinal disturbances see
Table 1. In addition to these recommendations, it might be ben-
eficial in some patients to try different solvents such as water or
juices to find out the optimal composition for intake of DFX. More-
over, to achieve a thorough dissolution of DFX in the chosen solvent,
electronic dispersers might be helpful.
Pre-prandial evening dosing still might be a reasonable
approach. Even if it does not reduce the incidence of gastrointesti-
nal disturbances in all cases, it might prevent interference with
daily routines of the patients by virtue of the GI disturbances being
at night.
For the management of diarrhea during DFX treatment the panel
recommends the algorithm shown in Fig. 2, which is a slightly mod-
ified version of the initial algorithm, i.e. administration of low doses
pre-prandial in the evening should be the starting schedule and
is not considered the alternative procedure, if the target morning
doses are not tolerated. For practical reasons a simple guidance
using the frequency of bowel movements has been applied in the
diarrhea management algorithm.
Fig. 1. Proposed dosing schedule. DFX should be initiated at a low dose in all patients. Target dose should be assessed according to the transfusion burden. It is important to
achieve  the target dose in a timely manner.
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Fig. 2. Algorithm for management of diarrhea.
The symptom “abdominal pain” requires an exact diagnosis
since management of upper and lower abdominal pain differs.
Switching a morning dose to an evening pre-prandial dosing should
be considered. Dosing before bedtime is not recommended due to
the risk of oesophageal irritation and bleeding. In cases of persisting
mild-to-moderate abdominal pain dose reductions should be con-
sidered before treatment interruptions. Reduction should be done
in steps of 5 mg/kg/day. If abdominal pain has resolved DFX dose
should be increased in 5 mg/kg/day steps to the target dose. Use
of antacids for upper abdominal pain might be considered. Spas-
molytic drugs might be helpful for lower abdominal pain. However,
analgesic drugs and non-steroidal anti-inflammatory drugs are not
recommended due to the common GI side effects of these drugs.
Temporary interruption of DFX treatment can be considered in
case of persisting severe abdominal pain until symptoms resolve.
DFX should then be reinitiated and the dose should be escalated
in 5 mg/kg/day steps. Of course, serious reasons for severe abdom-
inal pain should be ruled out. Recommendations are summarized
in Table 2.
Antiemetics such as metoclopramide can be used in case
of nausea and vomiting. Since vomiting is the only AE which
does not seem to improve with long-term use, pre-prandial
administration of DFX in the evening should be considered
especially if vomiting (and nausea) are related to the morn-
ing dose. In addition, administration of the drug in the evening
prevents, that gastrointestinal disturbances interfere with the
daily routines of the patients. Reduction of DFX in steps of
5 mg/kg/day should be done in cases of severe nausea/vomiting.
Re-initiation of DFX and increase on target should be done when
symptoms have resolved. Recommendations are summarized in
Table 3.
5. Alternative iron chelators and new formulations of
Deferasirox
In case DFX is judged inadequate in a patient, other chelators
can be considered. As mentioned above, DFO has shown efficacy in
patients with MDS  and IOL. Nevertheless, treatment adherence to
Table 2
Recommendations for management of abdominal pain Patients with constipation
have  to be managed by another algorithm!
Diagnosis is important
– Management of upper abdominal pain differs from lower abdominal pain
(with constipation and/or diarrhea and/or bloating)
Time of administration
– Anecdotal reports of benefit: patient is advised to refrain from solid foods
for 2 h after deferasirox
– Do not recommend DFX dosing before bedtime
Use of medication
– For upper abdominal pain, use anti-acidic drugs
–  Consider using spasmolytic drugs
– Do not use narcotic pain medications and non-steroidal anti-inflammatory
drugs
Dosing
–  Mild-to-moderate cases, consider DFX dose reduction before treatment
interruptions
•  Reduce DFX dose in steps of 5 mg/kg/day
• Increase DFX dosing in steps of 5 mg/kg/day on target when abdominal
pain has been resolved
– Severe cases: temporarily interrupt deferasirox until abdominal pain has
been resolved. Restart at low dose and increase in steps of 5 mg/kg/day on
target.
Table 3
Recommendations for management of nausea/vomiting.
Vomiting considered as a severe expression of nausea
–  Management of both similar
Use anti-emetics (metoclopramide)
Time of administration
– Strong notion that nausea (especially vomiting) might be related
to  the morning dosing, especially since vomiting is the only AE that
does not show a trend toward reduction with long-term use
Reduce DFX dosing in steps of 5 mg/kg/day in case of severe
nausea/vomiting
–  Increase dosing in steps of 5 mg/kg/day on target when
nausea/vomiting has been resolved
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DFO often is hampered by the inconvenience of its administration
i.e. continuous subcutaneous application for 24 h a day for sev-
eral days. Deferiprone is another oral available iron chelator that
is approved for treatment of IOL. Although it has shown its efficacy
in removing excess iron, Deferiprone is rather considered as a third
line drug, due to its side effects particularly induction of neutrope-
nia and agranulocytosis, respectively. However, Deferiprone can be
considered if DFX or DFO cannot be applied to a patient, but close
monitoring of differential blood counts should be done. A review
on the use of the different iron chelators in the treatment of IOL in
MDS  patients has been published recently [37].
Although the exact mechanisms of gastrointestinal intolerance
are not yet fully understood, osmotic mechanisms might play a
role in the development of diarrhea. Moreover, since DFX contains
lactose, patients with lactose intolerance might be more susceptible
to GI disturbances such as diarrhea.
A new formulation of DFX as a film coated tablet (FCT) has
been developed and is currently under investigation in clinical
trials. The FCT contains the same active substance as the dis-
persible formulation but lacks lactose and sodium sulphate that
have been implicated in the induction of gastrointestinal dis-
turbances. Moreover, pharmacokinetic studies demonstrated a
superior bioavailability of the FCT as compared to the dispersible
form with 360 mg  of the FCT equating to 500 mg  of dispersible DFX.
Interestingly, in contrast to DFX in the dispersible form, FCT seems
to lack a food effect with regard to its bioavailability, which might
facilitate administration of the drug and lead to a more predictable
drug exposure.
6. Brief summary and practical advice
- Data regarding IC in MDS  patients are controversial, but multiple
analyses suggest a benefit including erythroid improvement and
transfusion independence.
- Patients should be informed in detail about the nature of gastroin-
testinal disturbances.
- DFX dosing should be done pre-prandial in the evening for
patients with GI side effects.
- DFX should be initiated at low dose levels, e.g. 500 mg  per day.
- Escalation of DFX dose to target dose should be done in a timely
fashion.
- Target dose should be calculated based on serum ferritin and
transfusion frequency.
- New formulations might improve tolerability and adherence to
treatment.
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